Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK2461 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| MK2461 | DRUG | MK2461 treatment, bid, 28-day |
Inclusion Criteria: * Patients must be at least 18 years of age, with adequate organ function, and an ecog performance of \<2 Exclusion Criteria: * No chemotherapy, radiotherapy, or biological therapy with 4 weeks of study participation * Patients must not have primary central nervous system tumo...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
MK2461 is an investigational small molecule being developed for oncology indications, specifically for the treatment of advanced solid tumors and advanced cancer. It was studied in patients with neoplasms and advanced cancer in early-phase clinical trials. The drug is not approved and remains in clinical development.
MK2461 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company sponsored early-phase clinical trials of the drug in patients with advanced solid tumors and advanced cancer.
MK2461 is in Phase 1 clinical development. Two Phase 1 trials of the drug have been completed, one in patients with advanced solid tumors and one in patients with advanced cancer. The drug is investigational and has not been approved by regulatory authorities.
MK2461 has been studied in two completed Phase 1 clinical trials: NCT00496353, a Phase I/II study in patients with advanced solid tumors, and NCT00518739, a study in patients with advanced cancer. Both trials were uncontrolled and non-randomized, with a combined enrollment of 51 patients.
Yes, MK2461 and MK-2461 refer to the same investigational drug. Clinical trial records use both naming conventions, with the hyphenated form appearing in study titles such as 'MK-2461-002 AM1' and '2461-001'. Both names denote the same small molecule oncology candidate.